BACKGROUND: Cardiotoxicity is a well-known and potentially serious complication of anticancer therapy. Anthracycline-based chemotherapy represents the greatest risk. Early detection of cardiotoxicity is crucial for applying preventive and supportive therapeutic strategies. METHODS AND RESULTS: Various methods have been recommended for monitoring of cardiotoxicity. In our conditions, echocardiography and electrocardiography are routinely used. However, this approach shows low sensitivity for the early prediction of cardiomyopathy when the possibilities of appropriate management could still improve the patient's outcome. Recently, biomarkers of cardiac injury have been investigated in the assessment of chemotherapy-induced cardiotoxicity. Cardiospecific biomarkers, such as cardiac troponins, show high diagnostic efficacy in the early subclinical phase of the disease before the clinical onset of cardiomyopathy. Increase in their concentrations correlates with disease severity. As for natriuretic peptides, some studies, including ours, have shown promising results. Definitive evidence of their diagnostic and prognostic role in this context is still lacking and natriuretic peptides have not been routinely used for monitoring of cardiotoxicity in clinical practice. Other perspective biomarkers of cardiotoxicity in oncology are under study, especially heart-type fatty acid-binding protein (H-FABP) and glycogen phosphorylase BB (GPBB). Our studies using GPBB have provided encouraging results. However, the available data are limited and their practical use in this context cannot be recommended until their clinical efficacy is clearly defined. CONCLUSIONS: This review covers the current status of biomarkers for the early detection of anthracycline-induced cardiotoxicity. The authors present in brief, their own experience with multiple biomarkers in the detection of cardiotoxicity.

1st Department of Internal Medicine Cardioangiology Faculty of Medicine in Hradec Kralove Charles University Prague and University Hospital Hradec Kralove

4th Department of Internal Medicine Hematology Faculty of Medicine in Hradec Kralove Charles University Prague and University Hospital Hradec Kralove

Department of Internal Medicine Faculty of Military Health Sciences University of Defence Hradec Kralove Czech Republic

Institute of Clinical Biochemistry and Diagnostics University Hospital Hradec Kralove

000      

00000naa a2200000 a 4500

001      

bmc17006104

003      

CZ-PrNML

005      

20200211134804.0

007      

ta

008      

170210s2014 xr f 000 0|eng||

009      

AR

024    7_

$a 10.5507/bp.2014.004 $2 doi

035    __

$a (PubMed)24457832

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xr

100    1_

$a Horáček, Jan $u Department of Internal Medicine, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic; 4th Department of Internal Medicine - Hematology, Faculty of Medicine in Hradec Kralove, Charles University in Prague and University Hospital Hradec Kralove $7 xx0040415

245    10

$a Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status / $c J. M. Horacek, M. Vasatova, R. Pudil, M. Tichy, P. Zak, M. Jakl, L. Jebavy, J. Maly

520    9_

$a BACKGROUND: Cardiotoxicity is a well-known and potentially serious complication of anticancer therapy. Anthracycline-based chemotherapy represents the greatest risk. Early detection of cardiotoxicity is crucial for applying preventive and supportive therapeutic strategies. METHODS AND RESULTS: Various methods have been recommended for monitoring of cardiotoxicity. In our conditions, echocardiography and electrocardiography are routinely used. However, this approach shows low sensitivity for the early prediction of cardiomyopathy when the possibilities of appropriate management could still improve the patient's outcome. Recently, biomarkers of cardiac injury have been investigated in the assessment of chemotherapy-induced cardiotoxicity. Cardiospecific biomarkers, such as cardiac troponins, show high diagnostic efficacy in the early subclinical phase of the disease before the clinical onset of cardiomyopathy. Increase in their concentrations correlates with disease severity. As for natriuretic peptides, some studies, including ours, have shown promising results. Definitive evidence of their diagnostic and prognostic role in this context is still lacking and natriuretic peptides have not been routinely used for monitoring of cardiotoxicity in clinical practice. Other perspective biomarkers of cardiotoxicity in oncology are under study, especially heart-type fatty acid-binding protein (H-FABP) and glycogen phosphorylase BB (GPBB). Our studies using GPBB have provided encouraging results. However, the available data are limited and their practical use in this context cannot be recommended until their clinical efficacy is clearly defined. CONCLUSIONS: This review covers the current status of biomarkers for the early detection of anthracycline-induced cardiotoxicity. The authors present in brief, their own experience with multiple biomarkers in the detection of cardiotoxicity.

650    _2

$a antracykliny $x škodlivé účinky $7 D018943

650    _2

$a antibiotika antitumorózní $x škodlivé účinky $7 D000903

650    _2

$a biologické markery $x analýza $7 D015415

650    _2

$a kardiotoxicita $x diagnóza $x etiologie $7 D066126

650    _2

$a lidé $7 D006801

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

655    _2

$a přehledy $7 D016454

700    1_

$a Vašatová, Martina $7 xx0135924 $u Institute of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove

700    1_

$a Pudil, Radek $7 xx0040409 $u 1st Department of Internal Medicine - Cardioangiology, Faculty of Medicine in Hradec Kralove, Charles University in Prague and University Hospital Hradec Kralove

700    1_

$a Tichý, Miloš, $d 1941- $7 xx0112487 $u Institute of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove

700    1_

$a Žák, Pavel, $d 1966- $7 mzk2006354145 $u 4th Department of Internal Medicine - Hematology, Faculty of Medicine in Hradec Kralove, Charles University in Prague and University Hospital Hradec Kralove

700    1_

$a Jakl, Martin $7 xx0135493 $u Department of Internal Medicine, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic; 1st Department of Internal Medicine - Cardioangiology, Faculty of Medicine in Hradec Kralove, Charles University in Prague and University Hospital Hradec Kralove

700    1_

$a Jebavý, Ladislav, $d 1950- $7 mzk2007408362 $u Department of Internal Medicine, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic; 4th Department of Internal Medicine - Hematology, Faculty of Medicine in Hradec Kralove, Charles University in Prague and University Hospital Hradec Kralove

700    1_

$a Malý, Jaroslav, $d 1946- $7 nlk19990073524 $u 4th Department of Internal Medicine - Hematology, Faculty of Medicine in Hradec Kralove, Charles University in Prague and University Hospital Hradec Kralove

773    0_

$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic $x 1213-8118 $g Roč. 158, č. 4 (2014), s. 511-517

856    41

$u http://biomed.papers.upol.cz/ $y domovská stránka časopisu

910    __

$a ABA008 $b A 1502 $c 958 $y 4 $z 0

990    __

$a 20170210 $b ABA008

991    __

$a 20200211135158 $b ABA008

999    __

$a ok $b bmc $g 1192291 $s 966751

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2014 $b 158 $c 4 $d 511-517 $e 20140123 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606

LZP    __

$b NLK118 $a Pubmed-20170210